CVS - CVS Health Corporation
NYSE
->
Healthcare
->
Healthcare Plans
Woonsocket,
United States
Type: Equity
CVS price evolution
CVS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8196 | $13043 | $13807 | $14618 |
| Short term investments | $3259 | $3145 | $3080 | $3102 |
| Net receivables | $35227 | $32927 | $29546 | $28331 |
| Inventory | $18025 | $17954 | $17291 | $18263 |
| Total current assets | $67858 | $70143 | $67756 | $68706 |
| Long term investments | $23019 | $21667 | $22114 | $21612 |
| Property, plant & equipment | $30435 | $30586 | $30704 | $30532 |
| Goodwill & intangible assets | $120506 | $120885 | $121378 | $110425 |
| Total noncurrent assets | $181870 | $181163 | $182315 | $170624 |
| Total investments | $26278 | $24812 | $25194 | $24714 |
| Total assets | $249728 | $251306 | $250071 | $239330 |
| Current liabilities | ||||
| Accounts payable | $14897 | $14874 | $13367 | $12527 |
| Deferred revenue | ||||
| Short long term debt | $4713 | $3873 | $4108 | $3457 |
| Total current liabilities | $79189 | $81553 | $79206 | $75054 |
| Long term debt | $74672 | $76223 | $78028 | $73021 |
| Total noncurrent liabilities | $93903 | $95243 | $97863 | $92696 |
| Total debt | $79385 | $80096 | $82136 | $76478 |
| Total liabilities | $173092 | $176796 | $177069 | $167750 |
| Shareholders' equity | ||||
| Retained earnings | $61604 | $60343 | $58868 | $57753 |
| Other shareholder equity | -$297 | -$1004 | -$858 | -$875 |
| Total shareholder equity | $76461 | $74337 | $72726 | $71382 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8196 | $12945 | $9408 | $7854 |
| Short term investments | $3259 | $2778 | $3117 | $3000 |
| Net receivables | $35227 | $27276 | $24431 | $21742 |
| Inventory | $18025 | $19090 | $17760 | $18496 |
| Total current assets | $67858 | $65682 | $60008 | $56369 |
| Long term investments | $23019 | $21096 | $23025 | $20812 |
| Property, plant & equipment | $30435 | $30989 | $32018 | $33335 |
| Goodwill & intangible assets | $120506 | $102904 | $108147 | $110694 |
| Total noncurrent assets | $181870 | $162593 | $172991 | $174346 |
| Total investments | $26278 | $23874 | $26142 | $23812 |
| Total assets | $249728 | $228275 | $232999 | $230715 |
| Current liabilities | ||||
| Accounts payable | $14897 | $44667 | $12544 | $11138 |
| Deferred revenue | ||||
| Short long term debt | $4713 | $3456 | $5851 | $7078 |
| Total current liabilities | $79189 | $69736 | $67807 | $62017 |
| Long term debt | $74672 | $50476 | $70148 | $77964 |
| Total noncurrent liabilities | $93903 | $87224 | $89811 | $98997 |
| Total debt | $79385 | $70732 | $75999 | $85042 |
| Total liabilities | $173092 | $157260 | $157618 | $161014 |
| Shareholders' equity | ||||
| Retained earnings | $61604 | $56145 | $54906 | $49640 |
| Other shareholder equity | -$297 | $36 | $965 | $1414 |
| Total shareholder equity | $76461 | $71015 | $75075 | $69389 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $93813 | $89764 | $88921 | $85278 |
| Cost of revenue | $79937 | $76187 | $75318 | $71903 |
| Gross Profit | $13876 | $13577 | $13603 | $13375 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $10503 | $9876 | $9873 | $9580 |
| Total operating expenses | $10503 | $9887 | $10369 | $9929 |
| Operating income | $3373 | $3690 | $3234 | $3446 |
| Income from continuing operations | ||||
| EBIT | $3394 | $3708 | $3243 | $3462 |
| Income tax expense | $658 | $754 | $656 | $737 |
| Interest expense | $690 | $693 | $686 | $589 |
| Net income | ||||
| Net income | $2046 | $2261 | $1901 | $2136 |
| Income (for common shares) | $2046 | $2261 | $1901 | $2136 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $357776 | $322467 | $292111 | $268706 |
| Cost of revenue | $303345 | $268173 | $240063 | $219660 |
| Gross Profit | $54431 | $54294 | $52048 | $49046 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $39832 | $38212 | $37066 | $35135 |
| Total operating expenses | $40688 | $46548 | $38855 | $35135 |
| Operating income | $13743 | $7746 | $13193 | $13911 |
| Income from continuing operations | ||||
| EBIT | $13807 | $7899 | $12935 | $12655 |
| Income tax expense | $2805 | $1463 | $2522 | $2569 |
| Interest expense | $2658 | $2287 | $2503 | $2907 |
| Net income | ||||
| Net income | $8344 | $4149 | $7910 | $7179 |
| Income (for common shares) | $8344 | $4149 | $7910 | $7179 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $2046 | $2261 | $1901 | $2136 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | -$120 | -$18 | -$9380 | -$7094 |
| Stock-based compensation | ||||
| Total cash flows from operations | -$2636 | $2716 | $5908 | $7438 |
| Investing activities | ||||
| Capital expenditures | -$911 | -$545 | -$591 | -$984 |
| Investments | -$236 | -$219 | -$392 | -$467 |
| Total cash flows from investing | -$1242 | -$771 | -$10362 | -$8514 |
| Financing activities | ||||
| Dividends paid | -$779 | -$779 | -$795 | -$779 |
| Sale and purchase of stock | $36 | $125 | $26 | -$1922 |
| Net borrowings | -$232 | -$1947 | $4522 | $5589 |
| Total cash flows from financing | -$972 | -$2697 | $3626 | $2726 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4850 | -$752 | -$828 | $1650 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $8344 | $4149 | $7910 | $7179 |
| Operating activities | ||||
| Depreciation | $4247 | $4512 | $4441 | |
| Business acquisitions & disposals | -$16612 | -$1388 | -$146 | -$26 |
| Stock-based compensation | $447 | $484 | $400 | |
| Total cash flows from operations | $13426 | $16177 | $18265 | $15865 |
| Investing activities | ||||
| Capital expenditures | -$3031 | -$2727 | -$2520 | -$2437 |
| Investments | -$1314 | -$1017 | -$2717 | -$3071 |
| Total cash flows from investing | -$20889 | -$5047 | -$5261 | -$5534 |
| Financing activities | ||||
| Dividends paid | -$3132 | -$2907 | -$2625 | -$2624 |
| Sale and purchase of stock | -$1735 | -$2949 | $549 | $264 |
| Net borrowings | $7932 | -$4211 | -$9267 | -$5673 |
| Total cash flows from financing | $2683 | -$10516 | -$11356 | -$8155 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4780 | $614 | $1648 | $2176 |
News
|
CVS must face HIV patients' discrimination suit (NYSE:CVS)
Seeking Alpha
20 Apr 2024
|
|
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance
18 Apr 2024
|
|
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance
18 Apr 2024
|
|
Freeport-McMoRan, AppLovin And A Major Healthcare Stock On CNBC's 'Final Trades' - AppLovin...
Benzinga
17 Apr 2024
|
|
CVS favors Humira copycats hurting AbbVie’s market (NYSE:CVS)
Seeking Alpha
17 Apr 2024
|
|
Quant Ratings Updated on 64 Stocks
InvestorPlace
16 Apr 2024
|
|
Free Cash Flow ETFs See Continued Investor Interest
ETF Trends via Yahoo Finance
16 Apr 2024
|
|
Two CVS stores become the latest to join the national pharmacists unionization movement
USA TODAY via Yahoo News
12 Apr 2024
|
|
Fitch cites Medicare utilization impact on managed care
Seeking Alpha
10 Apr 2024
|
|
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
Zacks via Yahoo Finance
9 Apr 2024
|
Fundamentals
| Market cap | $87.29B |
|---|---|
| Enterprise value | $158.48B |
| Shares outstanding | 1.29B |
| Revenue | $357.78B |
|---|---|
| EBITDA | $13.81B |
| EBIT | $13.81B |
| Net Income | $8.34B |
| Revenue Q/Q | 11.89% |
| Revenue Y/Y | 10.95% |
| P/E ratio | 10.46 |
|---|---|
| EV/Sales | 0.44 |
| EV/EBITDA | 11.48 |
| EV/EBIT | 11.48 |
| P/S ratio | 0.24 |
| P/B ratio | 1.14 |
| Book/Share | 59.59 |
| Cash/Share | 6.36 |
| EPS | $6.48 |
|---|---|
| ROA | 3.37% |
| ROE | 11.32% |
| Debt/Equity | 2.26 |
|---|---|
| Net debt/EBITDA | 11.94 |
| Current ratio | 0.86 |
| Quick ratio | 0.63 |